What is the main business of Gelarry?

The main business activity of Gelarry focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 19, 2023.

Where is the headquarters located?

The headquarters is located at: ul. Kielecka 1, 31-523 Kraków.

Who is on the management board?

The management board consists of: Sofiia Mamonova (President of the Management Board) and Olena Parinova (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 10,000 (approx. $2,701).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of USD 285,910, representing an increase of 1486.9% compared to 2024.

Yes, in 2025 the company achieved a net profit of USD 28,204.

Which cost dominates operating expenses?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 152,934 in 2025, representing 62% of all operating expenses.

Gelarrysp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2023-05-19

Share capital

10 000,00 PLN

Registered address

ul. Kielecka 1/2, 31-523 Kraków, Poland

Financials

Revenue history (in k)

Filing timeliness

2 of 3 financial statements were filed late (the longest delay 260 days for 2023).

202520/07/2026
202414/07/2025
202301/04/2025

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 285.91kMedianUSD 1.06mAverageUSD 22.41m

Net profit

This companyUSD 28.20kMedianUSD 37.20kAverageUSD 879.46k

Operating costs

This companyUSD 248.31kMedianUSD 921.66kAverageUSD 21.08m

Assets

This companyUSD 246.87kMedianUSD 609.79kAverageUSD 11.85m

Industry

Authorized Representatives

Sofiia Mamonova – President of the Management Board

Olena Parinova – Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Sofiia Mamonovaage 26	50	$1,350.62	50%
Olena Parinovaage 21	50	$1,350.62	50%

The articles of association place no restrictions on share transfers.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2023-12-18.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Passimedsp. z o.o.	$1,761,047.56	passimed.pl
Medimessp. z o.o.	$1,317,775.92	medimes.pl
Model MedicalS.A.	$754,014.76	modelmedical.pl
Interforum Pharmasp. z o.o.	$710,214.55	interforumpharma.com
Softmedicasp. z o.o.	$481,553.31	softmedica.com.pl
Salpromedisp. z o.o.	$336,017.79	salpromedi.pl
MD International Medicalsp. z o.o.	$331,292.14	md-international.eu
CanpolandS.A.	$328,824.15	canpoland.com
Panacea-Diagnostykasp. z o.o.	$270,780.69	panacea.net.pl
PNN Pharmaceuticals sp. z o.o.sp. k.	$267,897.16	pnn.com.pl